Conart Sachet for Oral Solution

국가: 말레이시아

언어: 영어

출처: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

유효 성분:

Chondroitin Sulphate; Glucosamine Sulfate NaCl, Crystalline

제공처:

AV MANUFACTURING SDN.BHD

INN (International Name):

Chondroitin Sulphate; Glucosamine Sulfate NaCl, Crystalline

패키지 단위:

14 Sachets; 3 Sachets

Manufactured by:

AV MANUFACTURING SDN.BHD

환자 정보 전단

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _
CONART
® CAPSULE
Glucosamine Sulphate/ Chondroitin Sulphate (250mg/ 200mg)
CONART
® SACHET FOR ORAL SOLUTION
Glucosamine Sulphate/ Chondroitin Sulphate (1500mg/ 1200mg)
1
WHAT IS IN THIS LEAFLET
1.
What Conart is used for
2.
How Conart works?
3.
Before you take Conart
4.
How to use Conart
5.
While you are using Conart
6.
Side effects
7.
Storage and disposal
8.
Product description
9.
Manufacturer & product registration
holder
10. Date of revision
1.
WHAT CONART IS USED FOR
Conart is used to relieve joint problems
related to osteoarthritis.
2.
HOW CONART WORKS
Conart contains glucosamine which forms a
key part of cartilage (the cushioning substance
between bones in the joints) while chondroitin
acts by preventing damage or breakdown of
cartilage. Glucosamine and chondrotin act to
increase synovial fluid production, thereby
providing lubricant activity for proper joint
function.
3.
BEFORE YOU USE CONART
_-When you must not use it_

If you are allergic to glucosamine or
chondroitin or any of the ingredients in the
product.

If you are allergic to seafood.

Avoid use during the first 3 months of
pregnancy.
_-Before you start to use it_
Read the instruction and this leaflet
carefully to understand how this medication
should be taken.
Avoid use in children.
Tell your doctor or a pharmacist if you have
any medical conditions, especially any of the
following:

if you are pregnant, planning to become
pregnant, or breastfeeding.

if you have allergies to seafood, medicines
or other substances. This product contains
glucosamine
sulphate,
a
seafood-
derived material. It is not recommended for
people with seafood allergies.

if you have high blood glucose

if you have severe liver and /or kidney
problems
_-Taking other medicines_
Talk to your doctor or a pharmacist if
you are taking:

any medicine for diabetes (to control
the blood sugar), such as metformin,
acarbose, repaglinide.

Warfarin (a blood-thinning drug).
Glucosamine may increase the risk

제품 특성 요약

CONART CAPSULE
CONART SACHET FOR ORAL SOLUTION
NAME AND STRENGTH OF ACTIVE SUBSTANCES
CONART CAPSULE
: Glucosamine sulphate sodium chloride 314mg equivalent 250mg
glucosamine
sulphate (derived from seafood) and chondroitin sulphate 200mg
CONART SACHET
: Glucosamine sulphate sodium chloride 1884mg equivalent 1500mg
glucosamine
sulphate (derived from seafood) and chondroitin sulphate 95% purity
1265mg equivalent chondroitin
sulphate 1200mg
PRODUCT DESCRIPTION
CONART CAPSULE
: Hard gelatin bovine capsule, snap-fit dark maroon/white opaque
capsule with
embossed “Conart” at both side.
CONART SACHET
: Aluminium/PE sachet containing white to off-white powder
PHARMACODYNAMICS
Glucosamine is a natural substance found in chitin, mucoproteins, and
mucopolysaccharides. It is
involved in the manufacture of glycosaminoglycan, which forms
cartilage tissue in the body;
glucosamine is also present in tendons and ligaments. Glucosamine must
be synthesised by the body
but the ability to do this declines with age. Glucosamine and its
salts have therefore been advocated in
the treatment of rheumatic disorders including osteoarthritis.
Glucosamine also acts to improve the viscosity of synovial fluid by
increasing synovial fluid
production, thereby providing lubricant activity.
The primary mechanism of action of CS is increased joint
glycosaminoglycan concentration and a
subsequent enhancement of synovial fluid viscosity. Improvement in
joint structure and function
are due to: (1) increased endogenous synthesis of hyaluronic acid and
sulfated glycosaminoglycans
from chondroitin sulfates; and (2) reduced breakdown of joint
glycosaminoglycans subsequent to
decreased collagenolytic activity and inhibition of enzymes, such as
phospholipase A2 and N-
acetylglucosaminidase, which are capable of degrading existing joint
glycosaminoglycans.
Glucosamine and chondroitin work synergistically to stimulate the
anabolic metabolism of osteo-
cartilagineous tissues by stimulating the biosynthesis of the
mucopolysaccharides (which are the
essential